Overall, the effects of SLC25A32 inhibition on the proliferation of eight cancer cell lines are summarized in Figure 2C and indicate a clear separation between sensitive (cell growth normalized to NTC control <50%) and resistant cell lines (cell growth normalized to NTC control >75%). The gene discussed is SLC25A32; the disease is cancer.